VJOncology is committed to improving our service to you

Gathering Around Cancer 2020 | Osimertinib for EGFR-mutant lung cancer

VJOncology is committed to improving our service to you

Jarushka Naidoo

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines the approval and reimbursement of osimertinib in patients with EGFR mutant non-small cell lung cancer, based on the results of the FLAURA study. (NCT02296125). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter